NCT05621772Completed
Meridian Activation Remedy System for Parkinson's Disease
MARS-PD: Meridian Activation Remedy System for Parkinson's Disease - A Single-center, Rater-blinded, Parallel Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 5 Aug 2025
Brief summary (registry, in English)
In this study, the investigators aim to evaluate the clinical efficacy and cost-effectiveness of MARS-PD. Conventional, usual care will be used as the comparator because this trial aims to assess the add-on effect of MARS-PD. The investigators hypothesize that the complex therapy will relieve motor and nonmotor symptoms, improve gait performance, and enhance neuroplasticity in PD patients, and will be safe and cost-effective.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 88 (actual)
- First submitted
- 4 Nov 2022
- Start date
- 8 Apr 2022
- Primary completion date
- 3 Jul 2025
- Lead sponsor
- Korea Health Industry Development Institute
- Diseases
- Parkinson disease
- NCT number
- NCT05621772
What you commit to
- Study type: Interventional
- Participants enrolled: 88
- From 8 Apr 2022 to the primary completion date, 3 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- If there has been a change in the dosage of antiparkinsonian drugs (e.g., L-dopa, COMT (catechol-O-methyltransferase) inhibitor, Dopamine agonist, MAO-B (monoamine oxidase B) inhibitor, etc.) according to a doctor's prescription within the last 4 weeks prior to enrollment
- Patients who are receiving manual therapy, exercise therapy, or rehabilitation therapy for Parkinson's disease according to a doctor's prescription within the last 4 weeks prior to enrollment, or are planning to receive such therapy within the study period
Lab values
- Clinically unstable patients (e.g., elevated aspartate transaminase (AST) or alanine aminotransferase (ALT) more than three-fold the upper limit of normal in the research institute's laboratory, heart failure, respiratory failure, etc.)
Other
- Patients who are planning to undergo deep brain stimulation within the study period
- Pregnant or lactating women
- Patients with MMSE-K (Mini-Mental State Exam) score of 18 or less
- Patients who are not suitable for participation in this clinical study according to the judgment of the researcher
Who the study is looking for
- 45 to 75 years of age
- Patients with PD, diagnosed according to the United Kingdom Parkinson's Diseases Society Brain Bank Criteria
- Hoehn and Yahr scale stage I to III
- Patients who have voluntarily decided to participate in the clinical study and signed the informed consent form
Age in the registry: 45 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Trial Center, Daejeon Korean Medicine Hospital of Daejeon University Coordinator of this site? Confirm its status | Daejeon | South Korea | Unknown status |
Related publications
- Visual self-reporting for symptom communication in Parkinson's disease.Technol Health Care · 2026 · PMID 41641966
This page is information, not medical advice. Discuss any trial with your doctor.